A new study increases max-dose guidance for semaglutide. This offers hope for those who didn’t reach their weight goals. The ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of diabetes and obesity, while also delivering other health benefits, such as ...

Experts from five states have sounded the alarm about blockbuster weight loss drugs like Ozempic leaving users blind, ...

A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Sure, who wouldn’t want to lose a few pounds? But what’s really driving Hollywood’s latest trend is the drug’s seemingly miraculous side benefits ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a ...